Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long‐term follow‐up of the ESCAPE study

BACKGROUND: Previously, in the ESCAPE study, a randomized controlled trial, we found that 12 months of cilostazol administration significantly decreased coronary artery stenosis and the noncalcified plaque component compared with aspirin. The goal of the current study was to evaluate the effect of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohn, Minji, Chun, Eun Ju, Lim, Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426278/
https://www.ncbi.nlm.nih.gov/pubmed/35932165
http://dx.doi.org/10.1111/1753-0407.13300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426278/
https://www.ncbi.nlm.nih.gov/pubmed/35932165
http://dx.doi.org/10.1111/1753-0407.13300

Ejemplares similares